Crystalline form of sacubitril sodium salt
Provided are new crystalline forms A, B, C, D and E of sacubitril sodium salt and a method for preparation thereof, pharmaceutical compositions thereof, and application thereof in preparing drugs for enkephalinase-related diseases.
1. A crystalline form A of sacubitril sodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 6.0±0.2, 7.0±0.2, 11.8±0.2, 18.2±0.2, 19.7±0.2, and 23.5±0.2, expressed in degrees 2θ.
2. The crystalline form A of sacubitril sodium salt according to claim 1 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form A of sacubitril sodium salt shows an endothermic peak at around 168° C.
3. The crystalline form A of sacubitril sodium salt according to claim 1 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form A of sacubitril sodium salt shows an endothermic peak at around 166-169° C.
4. A crystalline form B of sacubitril sodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 5.1±0.2, 10.4±0.2, 11.2±0.2, 19.2±0.2, 19.7±0.2, 21.3±0.2, and 21.8±0.2, expressed in degrees 2θ.
5. The crystalline form B of sacubitril sodium salt according to claim 4 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form B of sacubitril sodium salt shows endothermic peaks at around 133° C. and 159° C.
6. The crystalline form B of sacubitril sodium salt according to claim 4 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form B of sacubitril sodium salt shows endothermic peaks at 130-134° C. and 149-160° C.
7. A crystalline form C of sacubitril sodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 6.5±0.2, 10.5±0.2, 11.2±0.2, 19.3±0.2, 21.4±0.2, 22.0±0.2, expressed in degree 20.
8. The crystalline form C of the sacubitril sodium salt according to claim 7 , which has a melting point of about 136±5° C.
9. A crystalline form D of sacubitril sodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 5.2±0.2, 8.7±0.2, 10.4±0.2, 12.2±0.2, and 15.7±0.2, expressed in degrees 2θ.
10. The crystalline form D of the sacubitril sodium salt according to claim 9 , which has a melting point of about 117±5° C.
11. A crystalline form E of sacubitril sodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 8.2±0.2, 10.4±0.2, 11.0±0.2, 13.9±0.2, 16.7±0.2, and 21.3±0.2, expressed in degree 2θ.
12. The crystalline form E of the sacubitril sodium salt according to claim 11 , which has a melting point of about 130±5° C.
13. A pharmaceutical composition, comprising:
the crystalline form A of sacubitril sodium salt according to claim 1 ; and
a pharmaceutically acceptable carrier.
14. A pharmaceutical composition, comprising:
the crystalline form B of sacubitril sodium salt according to claim 4 ; and
a pharmaceutically acceptable carrier.
15. A pharmaceutical composition, comprising:
the crystalline form C of sacubitril sodium salt according to claim 7 ; and
a pharmaceutically acceptable carrier.
16. A pharmaceutical composition, comprising:
the crystalline form D of sacubitril sodium salt according to claim 9 ; and
a pharmaceutically acceptable carrier.
17. A pharmaceutical composition, comprising:
the crystalline form E of sacubitril sodium salt according to claim 11 ; and
a pharmaceutically acceptable carrier.
18. A method for treating enkephalinase-related disease, comprising:
administering the crystalline form A of sacubitril sodium salt according to claim 1 to a subject in need thereof.
19. The method according to claim 18 , wherein the disease comprises heart failure, hypertension, and cardiomyopathy.